TY - JOUR T1 - A modest increase in <sup>11</sup>C-PK11195-PET TSPO binding in depression is not associated with serum C-reactive protein or body mass index JF - medRxiv DO - 10.1101/2020.06.04.20099556 SP - 2020.06.04.20099556 AU - Julia J. Schubert AU - Mattia Veronese AU - Tim D. Fryer AU - Roido Manavaki AU - Manfred G. Kitzbichler AU - Maria A. Nettis AU - Valeria Mondelli AU - Carmine M. Pariante AU - Edward T. Bullmore AU - NIMA Consortium AU - Federico E Turkheimer Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/05/2020.06.04.20099556.abstract N2 - BACKGROUND Immune mechanisms have been implicated in the pathogenesis of depression, and translocator-protein (TSPO) targeted positron emission tomography (PET) has been used to assess neuroinflammation in major depressive disorder. We aimed to: (i) test the prior hypothesis of significant case-control differences in TSPO binding in anterior cingulate (ACC), prefrontal (PFC) and insular (INS) cortical regions; and (ii) explore the relationship between cerebral TSPO binding and peripheral blood concentration of C-reactive protein (CRP).METHODS 51 depressed cases with Hamilton Depression Rating Scale score &gt; 13 (median 17; IQR 16-22) and 25 healthy matched controls underwent dynamic brain 11C-PK11195 PET and peripheral blood immune marker characterisation. Depressed cases were divided into high CRP (&gt;3mg/L;N=20) and low CRP (&lt;3mg/L;N=31).RESULTS Across the three regions, TSPO binding was significantly increased in cases vs controls (; F(1,71)=6.97, P=0.01). which was not influenced by differences in body mass index (BMI). The case-control difference was greatest in ACC (d=0.49; t(74)=2.00, .P=0.03) and not significant in PFC or INS (d=0.27; d=0.36). Following CRP stratification, significantly higher TSPO binding was observed in low CRP depression compared to controls (d=0.53; t(54)=1.96, P=0.03). These effect sizes are comparable to prior MDD case-control TSPO PET data. No significant correlations were observed between TSPO and CRP measures.CONCLUSIONS Consistent with previous findings, there is a modest increase in TSPO binding in depressed cases compared to healthy controls. The lack of a significant correlation between brain TSPO binding and blood CRP concentration or BMI poses questions about the interactions between central and peripheral immune responses in the pathogenesis of depression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe BIODEP study was sponsored by the Cambridgeshire and Peterborough NHS Foundation Trust and the University of Cambridge, and funded by a strategic award from the Wellcome Trust (104025) in partnership with Janssen, GlaxoSmithKline, Lundbeck and Pfizer. Recruitment of participants was supported by the National Institute of Health Research (NIHR) Clinical Research Network: Kent, Surrey and Sussex &amp; Eastern. Additional funding was provided by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London, and by the NIHR Cambridge Biomedical Research Centre (Mental Health). ETB and CMP are supported by a Senior Investigator award from the NIHR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the NRES Committee East of England Cambridge Central (REC reference:15/EE/0092) and the UK Administration of Radioactive Substances Advisory Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request, and upon approval from the research consortia. ER -